Likewise, several observations in breast cancer patients led to the hypothesis that low‐penetrance cancer susceptibility polymorphisms act as modifier genes in BRCA1/BRCA2 mutation carriers and non‐carriers to increase cancer risk. This evidence concerns the gene BRCA2 and cancer.